Market Place
Sourcing Support
All News #Library
Rare Diseases
Sentynl Therapeutics Enters into Agreement with PRG S&T
16 Mar 2026 //
PR NEWSWIRE
Zydus Gets USFDA Orphan Drug Designation For Desidustat
07 Feb 2026 //
INDPHARMAPOST
Zydus Secures USFDA Orphan Drug Status For Desidustat In Sickle
06 Feb 2026 //
ECONOMICTIMES
Zydus` Desidustat Receives USFDA Orphan Drug Designation
06 Feb 2026 //
EXPRESSPHARMA
Sentynl Therapeutics Inc. Announces FDA Approval of ZYCUBO
12 Jan 2026 //
PRESS RELEASE
Sentynl Therapeutics Announces FDA Acceptance Of CUTX-101 NDA
15 Dec 2025 //
PR NEWSWIRE
Sentynl Selects Mytomorrows To Lead Managed Access Program
10 Dec 2025 //
PR NEWSWIRE
Zydus Gets FDA Orphan Drug Designation For Desidustat
06 Nov 2025 //
INDPHARMAPOST
Fortress Bio, Cyprium Therapeutics Update NDA For CUTX-101
01 Oct 2025 //
GLOBENEWSWIRE
Zydus Therapeutics Reports Phase-3 Results in Rare Liver Disease
29 Aug 2025 //
INDPHARMAPOST
Zydus gets USFDA Fast Track for oral inhibitor Usnoflast
29 May 2025 //
INDPHARMAPOST
Zydus receives FDA Orphan Drug Designation for ALS
23 Jan 2025 //
ECONOMICTIMES
Sentynl Acquires Zokinvy® For Progeria From Eiger Globally
03 May 2024 //
PR NEWSWIRE
Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.